Scientists Just Used Three-Person DNA to Prevent Deadly Diseases in Babies
The method, sometimes called 'three-person IVF,' combines DNA from a mother, a father, and a donor to help families avoid passing on destructive mutations in mitochondrial DNA.
While most of our DNA comes from the mother and father's genetic material in the nucleus of a cell, mitochondria—the cell's power source—carry a tiny but critical amount of their own DNA. Mutations there can lead to devastating conditions, including muscle weakness, seizures, and organ failure.
For a small number of parents, traditional genetic testing can't always predict the risk of these conditions. That's where the three-person technique comes in.
Scientists extract healthy mitochondria from a donor egg and transfer the parents' genetic material into it before fertilization. The result? An embryo with healthy mitochondria and less than 1% donor DNA—too little to affect the child's traits, but enough to make a difference for their health.
'This marks an important milestone,' said Dr. Zev Williams of Columbia University Fertility Center. 'It's empowering more couples to pursue safe, healthy pregnancies.'
The procedure has been carefully regulated in the U.K. since 2016 and is approved only for patients who have no other options. Researchers at Newcastle University and Monash University in Australia reported that out of 22 patients treated, eight have delivered healthy babies. One woman is still pregnant.
However, some experts remain cautious. Critics warn of unknown long-term effects on future generations. In the U.S., federal law still prohibits clinical research involving heritable genetic modifications, keeping the technique off-limits for now.
For families who've faced mitochondrial disease, the potential is life-changing.
Liz Curtis, whose daughter Lily died from the condition in 2006, called the advance 'super exciting for families that don't have much hope.' Curtis now leads the Lily Foundation, which supports research into mitochondrial diseases, including this groundbreaking work.Scientists Just Used Three-Person DNA to Prevent Deadly Diseases in Babies first appeared on Men's Journal on Jul 18, 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
24 minutes ago
- Yahoo
France supports Belgium's push to block US destruction of contraceptives
France has confirmed it is monitoring a US plan to incinerate millions of dollars worth of unused contraceptives in Europe – a move aid groups say is ideologically driven and medically wasteful. The contraceptives – including intrauterine devices (IUDs), implants and pills – were bought under public health programmes run by the US Agency for International Development (USAID). Since January, the supplies have been sitting in a warehouse in Geel, Belgium, after the Trump administration froze and then cancelled funding for reproductive health projects. The products, which were meant for use in low- and middle-income countries, were being stored as part of USAID's supply chain, managed by its logistics contractor Chemonics. Several media outlets have reported that the material may soon be transferred and incinerated in France, though no final decision has been confirmed. A diplomatic source told RFI that France 'firmly supports the Belgian authorities' desire to find a solution to avoid the destruction of the contraceptives' and is 'following the situation closely'. The source added that France had 'no information about any transfers that have taken place'. A US State Department spokesperson told the French news agency AFP that a preliminary decision had been made to destroy certain "abortifacient contraceptives" from USAID contracts, adding that no HIV medication or condoms would be affected. The destruction is expected to cost $167,000. The stock is valued at $9.7 million. French left urges Macron not to be complicit in US plan to bin contraceptives Redistribution offers rejected Several global organisations say they offered to collect and redistribute the supplies free of charge, but were turned down by US authorities. The International Planned Parenthood Federation (IPPF) said it proposed to recover the products in Brussels, transport them to its Dutch warehouse for repackaging, and then send them to countries in need. MSI Reproductive Choices, a UK-based group, told RFI it had offered to cover all the costs involved, including rebranding. 'We would have removed the stars from the USAID logo. It would have cost the US taxpayer nothing, nor the government,' said Sarah Shaw, MSI's advocacy director. 'We were told the US government would only sell the supplies at their purchase price. This is a situation we have never seen before.' Shaw estimated the stock would have covered Senegal's contraception needs for three years. The UN's sexual and reproductive health agency, UNFPA, also offered to buy the contraceptives but was turned down. 'This suggests the problem is not legal, but ideological,' Shaw said. 'It is a clear refusal to allow these contraceptives to be given to women in need. This US administration simply does not recognise their right to contraception.' The US State Department has described the items as 'abortifacient' – a term commonly used by anti-abortion activists to describe IUDs and other hormonal contraceptives. Since January, the Trump administration has banned any US funding to NGOs that support or promote access to abortion, even indirectly. What's stopping more men in France from getting vasectomies? French firm denies involvement Media reports have identified Veolia, a French waste management firm, as a possible contractor for the incineration. But the company told RFI it only has a framework agreement with Chemonics to handle expired products. 'The stock mentioned in Belgium is not part of this agreement,' Veolia's press office said. 'We are not responsible for its management.' Activist Danièle Gaudry, from the coalition Abortion in Europe – Women Decide, told RFI the timing of any transfer from Belgium to France remains unknown. 'We still don't know the date it will happen, and we're still trying to identify the company,' she said. France's parliament approves free contraception to be extended to women up to the age of 25 Lawmakers urge action On Saturday, French Greens leader Marine Tondelier and a group of female MPs urged President Emmanuel Macron to intervene, calling the plan 'an affront to the fundamental principles of solidarity, public health and sexual and reproductive rights that France is committed to defending'. They asked him not to become 'complicit, even indirectly, in retrograde policies' and to support NGOs ready to redistribute the contraceptives. Sarah Durocher, president of the French Family Planning association, said France had a responsibility to act. 'A government that proudly enshrines the right to abortion in its constitution must also defend access to contraception beyond its borders,' she said, in a statement issued by IPPF. The Elysée has yet to comment on the case.
Yahoo
an hour ago
- Yahoo
Press Release: Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range
Q2: double-digit sales and solid business EPS growth. 2025 sales guidance is now high single-digit growth, at upper end of range Paris, July 31, 2025 Q2 sales growth of 10.1% at CER1 and business EPS2 of €1.59 Pharma launches increased sales by 39.8%, reaching €0.9 billion, driven by ALTUVIIIO Dupixent sales increased by 21.1% to €3.8 billion, supported by the COPD launch Vaccines sales increased by 10.3% to €1.2 billion Research and Development expenses were €1.9 billion, up 17.7% Selling, general and administrative expenses were €2.3 billion, up 7.8% Business EPS was €1.59, up 8.3% at CER and up 1.9% reported; IFRS EPS was €3.24 Pipeline progress Three regulatory approvals: Dupixent BP (US), Sarclisa NDMM, TE (EU), and MenQuadfi meningitis (US) Three phase 3 readouts, incl. itepekimab COPD (one met primary endpoint/one did not); positive SP0087 in rabies prevention Seven regulatory designations, including orphan and fast track, in rare diseases, neurology, and oncology Capital allocation Sanofi and CD&R closed the Opella transaction, creating an independent global consumer healthcare leader Acquisitions completed: Blueprint, in rare diseases/immunology, and Dren Bio's DR-0201, early-stage pipeline in immunology Acquisitions announced: Vigil, in Alzheimer's disease, and Vicebio, in respiratory vaccines, adding to the early-stage pipeline3 Sustainability Sanofi ranked the world's tenth most sustainable company and number one in Pharmaceuticals & Biotechnology by TIME Guidance In 2025, sales are anticipated to grow by a high single-digit percentage at CER (previously mid-to-high single-digit). Sanofi confirms the expectation of a strong business EPS rebound with growth at a low double-digit percentage at CER (before share buyback), now including all expenses from newly acquired businesses4 Sanofi intends to complete its €5 billion share buyback program in 2025. 80.3% has been repurchased to date Paul Hudson, Chief Executive Officer: 'We delivered strong performance in Q2 with 10.1% sales growth. Our nine newly launched medicines and vaccines grew by 47.3%. Eight years after market introduction, Dupixent grew by more than 20%, supported by the COPD launch. Based on strong sales performance in H1, we are refining our 2025 sales guidance to the upper end of our previous range. At the same time, we confirm our guidance of a strong business EPS rebound, which now includes all expenses from newly acquired businesses. Our pipeline continues to make progress despite the mixed results with itepekimab in COPD. We are progressing the data analysis and once finished, we will discuss with regulatory authorities. We remain steadfast in our dedication to bringing new medicines and vaccines to patients. We eagerly anticipate several important phase 3 data readouts in the second half of the year, including amlitelimab in atopic dermatitis and tolebrutinib in primary progressive multiple sclerosis. Earlier in July, we successfully closed the acquisition of Blueprint in rare diseases, and we are anticipating the closing of the Vigil acquisition in neurology during Q3. Sanofi will remain focused on strategically redeploying capital towards growth and differentiated science with attractive financial returns. We continue to advance our strategy as an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth.' Q2 2025 Change Change at CER H1 2025 Change Change at CER IFRS net sales reported €9,994m +6.0% +10.1% €19,889m +8.3% +9.9% IFRS net income reported €3,939m +253.9% — €5,812m +158.8% — IFRS EPS reported €3.24 +264.0% — €4.74 +163.3% — Free cash flow5 €1,429m +65.8% — €2,458m +474.3% — Business operating income €2,461m -2.4% +3.3 % €5,363m +8.6% +10.8% Business net income €1,940m -0.6% +5.1 % €4,152m +7.6% +9.8% Business EPS €1.59 +1.9% +8.3% €3.39 +9.7% +12.0% 1 Changes in net sales are at constant exchange rates (CER) unless stated otherwise (definition in Appendix 9). 2 To facilitate an understanding of operational performance, Sanofi comments on the business net income, a non-IFRS financial measure (definition in Appendix 9). The income statement is in Appendix 3 and a reconciliation of net income as reported under IFRS to business net income is in Appendix 4. 3 Subject to closing conditions detailed overleaf. 4 Applying July 2025 average currency exchange rates, the currency impacts are estimated at around -4% on sales and at around -6% on business EPS. 5 Free cash flow is a non-IFRS financial measure (definition in Appendix 9). Attachment Press releaseError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Soaring numbers of Inverclyde kids going to A&E for emergency dental treatment
SHOCKING new figures show the number of children in Inverclyde needing emergency treatment for tooth decay has soared. The statistics, released through freedom of information legislation, show the number of patients under 18 attending both Inverclyde Royal and the Royal Hospital for Children has doubled in the last five years. Health board figures also show that in total 133 men, women and children attended Inverclyde Royal for dental care over that period of time. Across Greater Glasgow and Clyde, there was a huge 109 per cent increase in hospital attendances for emergency dental treatment - and nearly a third of all visits to A&E for issues relating to tooth decay were by children. The figures underline the crisis in NHS dental provision in Inverclyde, with increasing numbers of local residents forced to travel miles to find an NHS dentist as local practices shut down or close their NHS lists to new patients. Inverclyde MP Martin McCluskey says he fears the new figures are only 'the tip of the iceberg'. (Image: George Munro) In response to the local crisis, which saw Inverclyde labelled a 'dental desert', funding was made available to encourage practices to open up in the area. Plans for a new practice in the Waterfront Retail Park were approved by Inverclyde Council earlier this year, but Mr McCluskey says he believes the crisis in local NHS dentistry is undermining years of efforts to improve children's teeth. Following his FOI request, Mr McCluskey told the Telegraph: "People across our area know from their own experience how difficult it is to find a dentist. 'These figures demonstrate beyond doubt that the SNP are asleep at the wheel when it comes to dental care in our area. "The Scottish Government have promised time and again to reform the NHS and get to grips with the health and social care crisis, and time and again they have failed. 'So much work has been undertaken over the years to improve children's teeth and to set them up for the rest of their lives. 'This risks being undone by poor access to dentistry and a system that is creaking locally. READ MORE: Inverclyde patients face 36-mile round trip to sign up with NHS dentast as local crisis deepens Inverclyde dental crisis sparks calls to bring back local emergency clinics Dentist reveals hopes for new Greenock practice - along with planned opening date Inverclyde 'dental desert' crisis highlighted in Scottish Parliament debate "These statistics are likely only the tip of the iceberg. I expect many more children will have been treated as emergency cases at local dentists. "These cases represent the most extreme situations where children have clearly been left in so much pain that parents have had no other option than to taken them to A&E." In June 2024, emergency dental clinics in Greenock Health Centre were piloted for a short time following the closure of MyDentist in George Square. Mr McCluskey launched a campaign last year to improve NHS dental provision in the area after the Ardgowan Practice in Greenock stopped treating patients on the NHS, blaming government underfunding and a rise in running costs. He added: "It is clear that this situation, already bad before the pandemic, has been allowed to deteriorate since then, and this will continue unless pressure is applied to force the Scottish Government to act.' (Image: George Munro) A Scottish Government spokesperson said: 'Our commitment to improving NHS dentistry means communities in Inverclyde and across Scotland will benefit from an increase of almost 15 per cent in funding for primary care dental services planned this year - taking total funding to over half a billion pounds for the first time. "It also includes investment of up to £3 million to improve access and support the NHS dental workforce.' They went on to highlight the flagship Childsmile programme focuses on ensuring every child in Scotland has access to high-quality dental services. The spokesperson added: "The latest National Dental Inspection Programme figures show that 73 per cent of children in Primary 1 have no obvious tooth decay compared with just 58 per cent when it was introduced in 2008. 'The gap between Primary 1 children with no obvious tooth decay living in the most and least deprived areas is the lowest on record. Soaring numbers of children in Inverclyde are attending A&E for emergency dental treatment, new figures have revealed. (Image: Canva) 'Whilst we have more work to do, it's worth noting over one million patients were seen by an NHS dentist between January and March 2025, and Scotland is the only country in the UK that offers free, regular dental examinations for all." A spokesperson for NHS Greater Glasgow and Clyde said: " We are continuing to work with general dental practitioners and colleagues within Inverclyde HSCP to identify initiatives to support access to emergency dental care. "Inverclyde also remains an area where Scottish Dental Access Initiative (SDAI) funding is available to support new practices opening in the area, and this initiative has led to one formal application being progressed through due process."
